Table 3.

Relapse free survival and metastasis free survival

	Relapse free survival		Metastasis free survival
	Five-year	P	Five-year	P
Total patients	34.4 ± 4.0	N/A	33.6 ± 3.9	N/A
Age
≤11(F), ≤12(M)	39.8 ± 14.2		26.6 ± 14.4
12–14 (F), 13–15 (M)	37.3 ± 10.0		35.4 ± 9.6
15–39 (F), 16–39 (M)	33.3 ± 7.0		33.2 ± 6.7
≥40	37.5 ± 28.6	0.941	37.5 ± 28.6	0.952
Gender
Male	32.1 ± 6.3		31.9 ± 5.9
Female	41.9 ± 10.0	0.090	38.0 ± 9.7	0.053
Location
Distal Femur	37.3 ± 7.7		32.4 ± 7.2
Proximal Tibia	45.9 ± 9.9		41.8 ± 9.4
Proximal humerus	25.0 ± 20.4		25.0 ± 20.4
Proximal fibula	30.7 ± 17.1		46.0 ± 17.5
Proximal Femur	25.0 ± 21.7		0
Hip/Pelvic	0		0
Others	0	0.454	57.1 ± 18.7	0.257
Pathological Fracture
Yes	0		0
No	37.1 ± 5.5	0.319	35.5 ± 5.2	0.386
Subtype
Osteoblast	33.5 ± 5.7		31.9 ± 5.4
Chondroblastic	29.3 ± 15.3		29.3 ± 15.3
Fibroblastic	66.7 ± 19.2		83.3 ± 15.2
Others	45.0 ± 32.2	0.257	33.8 ± 26.0	0.326
Chemotherapy
Optimal Chemotherapy	49.0 ± 7.2		39.5 ± 6.7
Suboptimal Chemotherapy	30.4 ± 6.0	0.009*	24.7 ± 6.1	0.005*
Local Recurrence
Yes	—		13.7 ± 8.0
No	—	—	40.3 ± 5.8	0.033*
Distal Metastasis
Yes	21.1 ± 6.1		—
No	50.1 ± 7.8	0.001*	—	—

*,P<0.05; F, female; M, male.